a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)
(,

Application Number			10533045		
	Filing Date		2005-10-20		
	First Named Inventor Lepha		art et al.		
	Art Unit		1617		
	Examiner Name	Sheng	gjun Wang		
	Attorney Docket Numb	er	47-06		

U.S.PATENTS						
Examinor Cite No Patent Number Kind Code! Issue Date Name of Patentee or Applicant Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear					Relevant Passages or Relevant	
	1					
If you wish to add additional U.S. Patent citation information please click the Add button.						

U.S.PATENT	APPLICATION	PUBLICATION

Examiner Initial*	Cite No		Kind Code <sup>1</sup>		Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code2i	Kind Code4	Publication	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS	
	1								

If you wish to add additional Foreign Patent Document citation information please click the Add button

## NON-PATENT LITERATURE DOCUMENTS

		NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	T5	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10533045
iling Date		2005-10-20
irst Named Inventor Lepha		art et al.
rt Unit		1617
xaminer Name Sheng		ajun Wang
ttomey Docket Numb	er	47-06

1	Products 46(6):852-861, NovDec. 1983	giazepam-like: compounds from bowne urine, Journal of Natura	•

If you wish to add additional non-patent literature document citation information please click the Add button

F

Е

### EXAMINER SIGNATURE

Examiner Signature | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

See Not Codes of USPTO Petert Documents at sew USETO CGDV or MPER 901.04. \* Enter of this that issued the document, by the stool-later code (NIPO) Stoodard 51.3). \*\*Stoodard 51.3). \*\*Stoodard 51.3.\*\* Stoodard 51.3.\*\* Stoodard

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10533045
Filing Date		2005-10-20
First Named Inventor Lepha		art et al.
Art Unit		1617
Examiner Name Sheng		ajun Wang
Attorney Docket Number		47-06

#### CERTIFICATION STATEMENT

Diagon one 27	CED 4	07 and	1 98 to make the appropriate sele	notion(a):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

### OR

That no term of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no term of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See 37 CFR 1.39(c) and the statement. See

_	See	attached	certification	statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☑ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on the agriculture.					
Signature	/sjpennerREG54371/	Date (YYYY-MM-DD)	2007-03-28		
Name/Print	Steven J. Penner	Registration Number	54371		

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life find by the USPTO to process) an application. Confidentiality is governed by \$5 U.S.C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P.O. 80x 1450, Alexandria, V.S.2313-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, V.S.2313-1450.

### **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached from related to a petent application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) furnishing of the information solicided that: (1) the general authority for the collection of this information is used by the U.S. Patient and Trademax Ciffic is to process and/or oximality your submission related to a patient application or patient. If you do not furnish the requested process and/or oximality your submission related to a patient application or patient. If you do not furnish the requested many control or the patient of the patien

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. SS2(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a noutine use, to the Administrator, General Services, or hisher desligner, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to \$5 U.S.C. 152(b) or issuance of a patent pursuant to \$5 U.S.C. 151. Further, a record may be disclosed, subject to the limitation of 37 CFR 1.14, as a routine use, by the public if the accord was filled in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency. If the USPTO becomes aware of a violation or potential violation of law or regulation.